68 Ga-DOTANOC PET/CT in Multiple Endocrine Neoplasia 1 With Associated Adrenocortical Carcinoma
Shyma Basheer, MD, ** Ramkesh Ratheesan, MBBS,¡ Manjit Sarma, DNB, ** Shanmuga Sundaram Palaniswamy, DNB, ** and Anitha Mathews, MD±
Abstract: Multiple endocrine neoplasia 1 (MEN1) syndrome is an autoso- mal dominant syndrome comprising a triad of pancreatic, pituitary, and parathyroid tumors. Adrenal cortical carcinoma occurs rarely in MEN1 syn- drome. Here, we have presented a case of a 62-year-old woman with adrenal mass and elevated serum parathormone levels, who underwent 68Ga- DOTANOC PET/CT. 68Ga-DOTANOC PET/CT showed intense tracer con- centration in the left adrenal mass and lesions in the liver, pancreas, and peri- toneum. Biopsy of the peritoneal deposit revealed metastatic adrenocortical carcinoma, and further genetic testing showed MEN1 mutation.
Key Words: 68Ga-DOTANOC, adrenocortical carcinoma, MEN1 syndrome, PET/CT
(Clin Nucl Med 2022;47: e389-e392)
Received for publication September 4, 2021; revision accepted December 30, 2021.
From the *Department of Nuclear Medicine and Molecular Imaging, ¡Amrita Vishwa Vidyapeetham, Kochi, Kerala, India; and įDepartment of Pathology, Regional Cancer Centre, Trivandrum, Kerala, India.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Shyma Basheer, MD, Department of Nuclear Medicine and Molecular Imaging, Amrita Institute of Medical Sciences and Research Centre, Kochi Kerala 682041, India. E-mail: shyma.b@gmail.com.
Copyright @ 2022 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0363-9762/22/4705-e389
DOI: 10.1097/RLU.0000000000004102
REFERENCES
1. Kharb S, Pandit A, Gundgurthi A, et al. Hidden diagnosis of multiple endo- crine neoplasia-1 unraveled during workup of virilization caused by adreno- cortical carcinoma. Indian J Endocrinol Metab. 2013;17:514.
2. Tripathy S, Prakash S, Arun Raj ST, et al. 3P’s of Wermer/MEN1 syndrome on 68Ga-DOTANOC PET/CT scan. Clin Nucl Med. 2020;45:e516-e517.
3. Bharwani N, Rockall AG, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011;196: W706-W714.
4. Almarzouq A, Asfar S, Hussain S, et al. Giant nonfunctioning adrenocortical carcinoma: a case report and review of the literature. BMC Res Notes. 2014;7:769.
5. Sharma P, Singh H, Dhull VS, et al. Adrenal masses of varied etiology: an- atomical and molecular imaging features on PET-CT. Clin Nucl Med. 2014;39:251-260.
6. Fareau GG, Vassilopoulou-Sellin R. Diagnostic challenges in adrenocortical carcinoma: recommendations for surveillance after surgical resection of se- lected adrenal nodules. Endocr Pract. 2007;13:636-641.
7. Sharma P, Singh H, Bal C, et al. PET/CT imaging of neuroendocrine tumors with (68)gallium-labeled somatostatin analogues: an overview and single in- stitutional experience from India. Indian J Nucl Med. 2014;29:2-12.
8. Lastoria S, Marciello F, Faggiano A, et al. Role of 68Ga-DOTATATE PET/ CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. 2016;52:488-494.
9. Leijon H, Remes S, Hagström J, et al. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol. 2019;86:66-75.
10. Pauwels E, Cleeren F, Bormans G, et al. Somatostatin receptor PET ligands -the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311-331.
11. Gezer E, Çetinarslan B, Cantürk Z, et al. Metastatic MEN1 syndrome treated with lutetium-177-a case report. Eur Endocrinol. 2019;15:92-94.
A
A
A
B
C
R
R
A
A
D
E
R
R
A
A
F
G
R
R
A
B
R
R
A
A
C
D
R
R
E
A
F
A
V
y
1
y
R
R
A
B
C